Newsroom News Archive Publications Contact Us for Experts
Media Contacts
Karen Kreeger
(215) 349-5658
Related Links
Perelman School of Medicine
University of Pennsylvania Health System
> Epigenetics Shapes Fate of Brain vs. Brawn Castes in Carpenter Ants
> Molecular Master Switch for Pancreatic Cancer Identified, Potential Predictor of Treatment Outcome
> Eat to Dream: Penn Study Shows Dietary Nutrients Associated with Certain Sleep Patterns
  All News Releases
    Media Resources
spacerNEWS RELEASE spacer Print Version
NOVEMBER 16, 2006
  Penn Professor Awarded J. Allyn Taylor International Prize in Medicine

(Philadelphia, PA) - Earlier this month, Mark I. Greene MD, PhD, the John Eckman Professor of Medical Science at the University of Pennsylvania School of Medicine, was awarded the J. Allyn Taylor International Prize in Medicine. The award is given by the Robarts Research Institute, which is based in London, Ontario, Canada. The prize is awarded annually to scientists who have made significant contributions to a field within one of Robarts’ principal areas of research.

Greene was awarded for his pioneering work leading to the development of Herceptin, the breast cancer drug that defines a new class of targeted cancer therapies. For more than 25 years, his research has focused on the molecular processes that underlie the development of breast and other cancers. His early work described how the activation of a particular receptor complex on the surface of cells led to the formation of aggressive breast tumors. His group then discovered how to disable this cancer-causing receptor complex. This paved the way for his and other laboratories to develop targeted antibodies and small molecules to block these receptors and stop tumor growth, without harming adjacent non-cancerous cells, as with chemotherapy or radiation. Greene is currently exploring the potential of targeted therapies to prevent cancer recurrence and treat advanced malignancies.

“The Taylor Prize is one of the few major international prizes for basic science and I am delighted to have received it,” says Greene.

He received $10,000 (Cdn), a medallion, and a certificate of merit at the Institute’s 20th Anniversary Dinner.


PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.


About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2016, The Trustees of the University of Pennsylvania